Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Opportunistic infections target people with weakened immune systems, including those with HIV. These conditions can lead to ...

Talking with the North Carolina Harm Reduction Coalition’s Loftin Wilson about the coalition’s work, how the opioid epidemic ...

Private sector leaders, philanthropists, and global health experts convened today at the B20 Global Health Breakout, held on the margins of the G20 Leaders' Summit, to spotlight a new wave of ...

Irish minister describes AMR as ‘one of the greatest global health challenges of our time’ as the government seeks to ...

The terms “gender ideology” and “transgender ideology,” have become ubiquitous — in government documents and policy announcements, in mass media and in online disputes.

The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...

The agency that distributed nearly half of all clean syringes provided to drug users in West Virginia last year will end its ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...